Evolent Health (NYSE:EVH) Price Target Lowered to $21.00 at Citigroup

Evolent Health (NYSE:EVH) had its price objective decreased by Citigroup from $33.00 to $21.00 in a report issued on Wednesday,Benzinga reports. Citigroup currently has a buy rating on the technology company’s stock.

A number of other analysts also recently weighed in on EVH. Barclays cut their price target on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating on the stock in a research report on Monday. KeyCorp assumed coverage on shares of Evolent Health in a report on Friday, October 11th. They issued an “overweight” rating and a $35.00 target price on the stock. JMP Securities decreased their price target on shares of Evolent Health from $34.00 to $31.00 and set a “market outperform” rating for the company in a report on Friday, August 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Evolent Health in a research note on Tuesday. Finally, Stephens cut Evolent Health from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $38.00 to $16.00 in a research note on Friday, November 8th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $29.50.

Evolent Health Trading Down 11.8 %

NYSE:EVH opened at $12.74 on Wednesday. The company has a current ratio of 1.04, a quick ratio of 1.08 and a debt-to-equity ratio of 0.58. Evolent Health has a 1-year low of $12.37 and a 1-year high of $35.00. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of -14.00 and a beta of 1.58. The business’s 50-day moving average price is $25.82 and its two-hundred day moving average price is $24.53.

Insider Transactions at Evolent Health

In other Evolent Health news, President Daniel Joseph Mccarthy sold 23,693 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.89, for a total transaction of $731,876.77. Following the completion of the transaction, the president now owns 198,809 shares of the company’s stock, valued at $6,141,210.01. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Evolent Health news, COO Emily Ann Rafferty sold 8,861 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total value of $265,830.00. Following the completion of the transaction, the chief operating officer now directly owns 63,408 shares in the company, valued at $1,902,240. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, President Daniel Joseph Mccarthy sold 23,693 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $30.89, for a total value of $731,876.77. Following the sale, the president now owns 198,809 shares in the company, valued at approximately $6,141,210.01. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 307,291 shares of company stock valued at $9,290,385 over the last three months. Company insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Evolent Health

Hedge funds and other institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. lifted its stake in Evolent Health by 125.0% in the first quarter. RA Capital Management L.P. now owns 5,736,132 shares of the technology company’s stock valued at $188,088,000 after acquiring an additional 3,187,000 shares during the last quarter. William Blair Investment Management LLC increased its holdings in shares of Evolent Health by 35.2% during the 2nd quarter. William Blair Investment Management LLC now owns 5,026,043 shares of the technology company’s stock worth $96,098,000 after acquiring an additional 1,308,376 shares during the last quarter. First Light Asset Management LLC increased its holdings in shares of Evolent Health by 401.5% during the 2nd quarter. First Light Asset Management LLC now owns 1,445,305 shares of the technology company’s stock worth $27,634,000 after acquiring an additional 1,157,124 shares during the last quarter. Engaged Capital LLC raised its stake in Evolent Health by 26.1% in the 2nd quarter. Engaged Capital LLC now owns 4,111,458 shares of the technology company’s stock valued at $78,611,000 after acquiring an additional 850,000 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in shares of Evolent Health by 24.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,048,341 shares of the technology company’s stock worth $39,164,000 after buying an additional 406,837 shares during the last quarter.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.